Clinical trials: Colon Cancer Stage I
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum
A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer
Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Conditions
- Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00060411
- Testing
- erlotinib hydrochloride, fluorouracil, leucovorin calcium
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00101972
- Testing
- monoclonal antibody RAV12
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- MacroGenics
Breast Cancer, Colorectal Cancer
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
RATIONALE: Bortezomib may stop the growth of solid tumors by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer
- Trial name
- NCT00620295
- Testing
- bortezomib, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Colorectal Cancer, Healthy, no Evidence of Disease
Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers
This randomized phase I trial studies the side effects and best dose of linaclotide acetate in preventing colorectal cancer in healthy volunteers. Chemoprevention is the use of certain drugs to keep cancer from forming.
- Trial name
- NCT01950403
- Testing
- linaclotide acetate, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Colorectal Cancer, Breast Cancer
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
SNB-101 is a novel nano-particle formulation of SN-38, the active metabolite of irinotecan(CPT-11). Study SNB101P01 is a multicenter, open-label, dose escalation, phase 1 study of SNB 101 with its active ingredient SN-38, in…
- Conditions
- Colorectal Cancer, Breast Cancer, Pancreas Cancer, Ovarian Cancer
- Trial name
- NCT04640480
- Testing
- SNB-101
- Where
- 3 sites in South Korea
- Volunteers
- 21 people
- Sponsor
- SN BioScience
Colorectal Cancer, Pancreatic Cancer
Vaccine Therapy Plus QS21 in Treating Patients With Advanced Pancreatic or Colorectal Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. QS21 may improve the ability of the immune system to respond to disease. Combining vaccine therapy with QS21 may kill more tumor cells.
- Trial name
- NCT00006387
- Testing
- QS21, ras peptide cancer vaccine
- Volunteers
- 7 people
- Sponsor
- Fox Chase Cancer Center
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients aged ≥ 18 years with solid tumors
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer
- Trial name
- NCT07261631
- Testing
- 68Ga-NNS309, 177Lu-DFC413
- Where
- 9 sites in United States, Canada and 5 more
- Volunteers
- 180 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumor
A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
In phase Ia study, the safety and tolerability of SI-B003 in patients with recurrent or metastatic solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum…
- Trial name
- NCT04606472
- Testing
- SI-B003
- Where
- 8 sites in China
- Volunteers
- 60 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Colorectal Cancer, Esophagus Cancer
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
This is a single-arm, open, dose-increasing phase I clinical study to explore the safety, tolerability and pharmacokinetic characteristics of the drug C-13-60 cells, and preliminarily observe the efficacy of the drug in CEA…
- Conditions
- Colorectal Cancer, Esophagus Cancer, Gastric Cancer, Pancreas Cancer
- Trial name
- NCT06043466
- Testing
- CEA-targeted CAR-T cells
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Advanced Colorectal Adenomas, Adenocarcinoma of the Colon
Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer
This phase II trial studies how well Polyphenon E works in treating patients with high-risk of colorectal cancer. Polyphenon E contains ingredients that may prevent or slow colorectal cancer.
- Conditions
- Advanced Colorectal Adenomas, Adenocarcinoma of the Colon, Stage I Colon Cancer, Stage II Colon Cancer
- Trial name
- NCT01606124
- Testing
- defined green tea catechin extract, questionnaire administration, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 39 people
- Sponsor
- Mayo Clinic
Colorectal Neoplasms, Hepatocellular Carcinoma
Dendritic Killer Cell-based Immunotherapy for Solid Tumors
The primary objective of this study is to evaluate the safety of autologous dendritic killer cell (DKC) in patients with metastatic solid tumor and to evaluate the maximum tolerated dose (MTD) of DKC.
- Conditions
- Colorectal Neoplasms, Hepatocellular Carcinoma, Neoplasm Metastasis
- Trial name
- NCT02882659
- Testing
- Dendritic Killer Cell (DKC)
- Volunteers
- 18 people
- Sponsor
- FullHope Biomedical Co., Ltd.
Colorectal Cancer
Liver Infusions of Fluorouracil in Treating Patients With Dukes' A, Dukes' B, or Dukes' C Colon Cancer Undergoing Surgery
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00427310
- Testing
- fluorouracil, Observation, sodium heparin
- Volunteers
- 1,158 people
- Sponsor
- NSABP Foundation Inc
Colorectal Cancer, Lung Cancer
Lapatinib and Cetuximab in Patients With Solid Tumors
This trial is for patients with colon cancer, head and neck cancer and lung cancer that has not responded to standard therapy. Cetuximab targets a receptor on cancer cells called the Epidermal Growth Factor Receptor or EGFR.
- Conditions
- Colorectal Cancer, Lung Cancer, Head and Neck Cancer
- Trial name
- TYKERB-ITUX 1 (NCT01184482)
- Testing
- cetuximab and lapatinib
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Georgetown University
Colorectal Cancer, Metastatic Colorectal Cancer
Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer
This phase I/II trial studies the best dose and side effects of glutaminase inhibitor CB-839 and how well it works with panitumumab and irinotecan hydrochloride (phase I only) in treating patients with RAS wildtype colorectal…
- Conditions
- Colorectal Cancer, Metastatic Colorectal Cancer, RAS Wild Type Colorectal Cancer, Refractory Colorectal Cancer
- Trial name
- NCT03263429
- Testing
- Glutaminase Inhibitor CB-839, Panitumumab, Irinotecan Hydrochloride (phase I only)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Colorectal Cancer, High Grade Serous Ovarian Cancer
A Phase I Trial of LY3143921 Hydrate in Solid Tumours
This clinical study looked at a drug called LY3143921 hydrate (a Cdc7 inhibitor) in adult patients with advanced solid tumours. The main aims were to find out the maximum dose of LY3143921 hydrate that could be given safely to…
- Conditions
- Colorectal Cancer, High Grade Serous Ovarian Cancer, Non Small-cell Lung Cancer (Squamous Cell Variant), Urothelial Cancer
- Trial name
- NCT03096054
- Testing
- LY3143921 hydrate
- Where
- 4 sites in United Kingdom
- Volunteers
- 69 people
- Sponsor
- Cancer Research UK
Peritoneal Carcinomatosis, Colorectal Cancer
Multi-modality Imaging in Peritoneal Carcinomatosis of Colorectal Origin
Intraoperative tumor localization and resection can be enhanced using intraoperative fluorescence imaging and radiodetection. Labetuzumab specifically recognizes CEA which is is expressed on > 95% of colorectal cancers..
- Conditions
- Peritoneal Carcinomatosis, Colorectal Cancer, Carcinoma, Neoplasms
- Trial name
- MMIPC (NCT03699332)
- Testing
- Indium-111-DOTA-Labetuzumab-IRDye800CW injection, SPECT/CT scan, CRS extended with dual-modality imaging
- Where
- Netherlands
- Volunteers
- 29 people
- Sponsor
- Radboud University Medical Center
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Pain, Bladder Cancer
Study of D-Methadone in Patients With Chronic Pain
The purpose of this study is to determine the safest dose of d-methadone that can be given, without causing severe side effects in most patients with chronic pain.
- Conditions
- Pain, Bladder Cancer, Breast Cancer, CNS Cancer
- Trial name
- NCT00588640
- Testing
- d-Methadone
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer
Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC
This is a phase I/II multi-center open-label proof of concept study, consisting of two parts. Part A of this study is designed to identify the recommended phase 2 dose (RP2D) of the combination regimen of dacomitinib plus…
- Trial name
- M13DAP (NCT02039336)
- Testing
- Dacomitinib, PD-0325901, Docetaxel
- Where
- 3 sites in Netherlands
- Volunteers
- 35 people
- Sponsor
- The Netherlands Cancer Institute
Breast Carcinoma, Colorectal Carcinoma
Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer
This phase I trial studies the side effects and best dose of M5A-IL2 immunocytokine (M5A-ICK) combined with stereotactic body radiation therapy (SBRT) and to see how well they work in treating patients with colorectal cancer or…
- Trial name
- NCT06130826
- Testing
- Biopsy, Biospecimen Collection, Bone Scan
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- City of Hope Medical Center